— outputs: – name: タイトル desc: 記事のタイトルを日本語に翻訳 input: article: | Until recently, clinicians could only counsel lifestyle changes for patients with metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH). Now, with the FDA’s approvals of semaglutide and resmetirom, treatment choices have expanded for patients whose disease has advanced to MASH.An Increasingly Common DiseaseMASLD has emerged as a leading cause of chronic liver disease, driven by the increased prevalence of metabolic disorders such as diabetes and obesity.The Power of GLP-1sThe ESSENCE study, published in The New England Journal of Medicine, found that 2.4 mg of semaglutide once a week improved liver histology in patients with MASH and moderate or advanced fibrosis. GLP-1s, like semaglutide, may be appropriate for patients with coexisting obesity or diabetes, though gastrointestinal-related adverse effects and access issues could limit its use.Resmetirom’s Targeted ApproachResmetirom acts directly on liver cells to improve lipid metabolism and may help reduce fibrosis. The MAESTRO-NASH trial, published in The New England Journal of Medicine, included adults with biopsy confirmed MASH and F2-F3 fibrosis and found resmetirom 80 mg and 100 mg produced MASH resolution without a worsening of fibrosis. Resmetirom is currently recommended only for patients with F2-F3 fibrosis. Gastrointestinal-related adverse effects are also common with this drug.Matching Drug to PatientThe choice of drug should be individualized on the basis of comorbidities. For example, GLP-1s, like semaglutide, may be beneficial for patients with coexisting diabetes or obesity, whereas resmetirom may be better suited for those with advanced liver disease, low BMI, or an inability
医科

— outputs: – name: タイトル desc: 記事のタイトルを日本語に翻訳 input: article: | Until recently, clinicians could only counsel lifestyle changes for patients with metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH). Now, with the FDA’s approvals of semaglutide and resmetirom, treatment choices have expanded for patients whose disease has advanced to MASH.An Increasingly Common DiseaseMASLD has emerged as a leading cause of chronic liver disease, driven by the increased prevalence of metabolic disorders such as diabetes and obesity.The Power of GLP-1sThe ESSENCE study, published in The New England Journal of Medicine, found that 2.4 mg of semaglutide once a week improved liver histology in patients with MASH and moderate or advanced fibrosis. GLP-1s, like semaglutide, may be appropriate for patients with coexisting obesity or diabetes, though gastrointestinal-related adverse effects and access issues could limit its use.Resmetirom’s Targeted ApproachResmetirom acts directly on liver cells to improve lipid metabolism and may help reduce fibrosis. The MAESTRO-NASH trial, published in The New England Journal of Medicine, included adults with biopsy confirmed MASH and F2-F3 fibrosis and found resmetirom 80 mg and 100 mg produced MASH resolution without a worsening of fibrosis. Resmetirom is currently recommended only for patients with F2-F3 fibrosis. Gastrointestinal-related adverse effects are also common with this drug.Matching Drug to PatientThe choice of drug should be individualized on the basis of comorbidities. For example, GLP-1s, like semaglutide, may be beneficial for patients with coexisting diabetes or obesity, whereas resmetirom may be better suited for those with advanced liver disease, low BMI, or an inability

MASLD/MASH治療の新たな展望：セマグルチドとレスメチロムの登場 これまで、代謝機能不全関連脂肪性肝疾患（MASLD）または代謝機能不全関連脂肪肝炎（M…